WallStSmart

BrightSpring Health Services, Inc. Common Stock (BTSG)vsMangoceuticals, Inc. Common Stock (MGRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BrightSpring Health Services, Inc. Common Stock generates 3291462% more annual revenue ($13.65B vs $414,580). BTSG leads profitability with a 2.3% profit margin vs 0.0%. BTSG earns a higher WallStSmart Score of 53/100 (C-).

BTSG

Buy

53

out of 100

Grade: C-

Growth: 8.7Profit: 5.0Value: 4.0Quality: 6.0
Piotroski: 5/9Altman Z: 2.65

MGRX

Avoid

23

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: 2.57

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTSG2 strengths · Avg: 9.0/10
EPS GrowthGrowth
359.8%10/10

Earnings expanding 359.8% YoY

Revenue GrowthGrowth
25.6%8/10

Revenue surging 25.6% year-over-year

MGRX2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Areas to Watch

BTSG4 concerns · Avg: 2.8/10
Profit MarginProfitability
2.3%3/10

2.3% margin — thin

Operating MarginProfitability
3.4%3/10

Operating margin of 3.4%

Debt/EquityHealth
1.363/10

Elevated debt levels

P/E RatioValuation
79.2x2/10

Premium valuation, high expectations priced in

MGRX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.35M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BTSG

The strongest argument for BTSG centers on EPS Growth, Revenue Growth. Revenue growth of 25.6% demonstrates continued momentum.

Bull Case : MGRX

The strongest argument for MGRX centers on Price/Book, Debt/Equity.

Bear Case : BTSG

The primary concerns for BTSG are Profit Margin, Operating Margin, Debt/Equity. A P/E of 79.2x leaves little room for execution misses. Thin 2.3% margins leave little buffer for downturns.

Bear Case : MGRX

The primary concerns for MGRX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

BTSG profiles as a growth stock while MGRX is a value play — different risk/reward profiles.

MGRX carries more volatility with a beta of 2.27 — expect wider price swings.

BTSG is growing revenue faster at 25.6% — sustainability is the question.

BTSG generates stronger free cash flow (101M), providing more financial flexibility.

Bottom Line

BTSG scores higher overall (53/100 vs 23/100) and 25.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BrightSpring Health Services, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

BrightSpring Health Services, Inc. (BTSG) is a leading provider of home and community-based health services, specializing in the care of diverse patient populations, including individuals with intellectual and developmental disabilities and those in need of rehabilitation. The company is committed to delivering personalized, high-quality care through a skilled workforce, which contributes to improved patient outcomes and enhances quality of life. With a focus on strategic investments in innovative technologies and a robust approach to value-based care, BrightSpring is well-positioned to thrive in the dynamic healthcare environment and capitalize on emerging market opportunities.

Visit Website →

Mangoceuticals, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Mangoceuticals, Inc. focuses to develop, market, and sell various men's wellness products and services through a telemedicine platform. The company is headquartered in Dallas, Texas.

Visit Website →

Want to dig deeper into these stocks?